FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895933654> ?p ?o ?g. }

• W2895933654 endingPage "35342" @default.
• W2895933654 startingPage "35327" @default.
• W2895933654 abstract "// Amro Aboukameel 1 , Irfana Muqbil 2 , Erkan Baloglu 3 , William Senapedis 3 , Yosef Landesman 3 , Christian Argueta 3 , Michael Kauffman 3 , Hua Chang 3 , Trinayan Kashyap 3 , Sharon Shacham 3 , Jasper E. Neggers 4 , Dirk Daelemans 4 , Elisabeth I. Heath 1 and Asfar S. Azmi 1 1 Wayne State University School of Medicine, Detroit, MI, USA 2 University of Detroit Mercy, Detroit, MI, USA 3 Karyopharm Therapeutics Inc, Newton, MA, USA 4 KU Leuven Department of Microbiology and Immunology, Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, Herestraat, Belgium Correspondence to: Elisabeth I. Heath, email: heathe@karmanos.org Asfar S. Azmi, email: azmia@karmanos.org Keywords: metastatic prostate cancer; AR SPLICE variant; nuclear export; CRM1; SINE Received: July 12, 2018      Accepted: October 06, 2018      Published: October 19, 2018 ABSTRACT Emerging studies have shown that the expression of AR splice variants (ARv) lacking ligand-binding domain is associated with castrate-resistant prostate cancer (CRPC) and higher risk of tumor metastasis and recurrence. Nuclear export protein XPO1 regulates the nuclear localization of many proteins including tumor suppressor proteins. Increased XPO1 in prostate cancer is associated with a high Gleason score and bone metastasis. In this study, we found that high expression of AR splice variant 7 (AR-v7) was correlated with increased XPO1 expression. Silencing of XPO1 by RNAi or treatment with Selective Inhibitor of Nuclear Export (SINE) compounds selinexor and eltanexor (KPT-8602) down-regulated the expression of AR, AR-v7 and ARv567es at mRNA and protein levels. XPO1 silencing also inhibited the expression of AR and ARv regulators including FOXA1, Src, Vav3, MED1 and Sam68, leading to the suppression of ARv and AR target genes, UBE2C and PSA. By targeting XPO1/ARv signaling, SINE suppressed prostate cancer (PCa) growth in vitro and in vivo and potentiated the anti-cancer activity of anti-AR agents, enzalutamide and abiraterone. Therefore, XPO1 inhibition could be a novel promising agent used in combination with conventional chemotherapeutics and AR-targeted therapy for the better treatment of PCa, especially CRPC." @default.
• W2895933654 created "2018-10-26" @default.
• W2895933654 creator A5000198604 @default.
• W2895933654 creator A5015865144 @default.
• W2895933654 creator A5026049304 @default.
• W2895933654 creator A5038465132 @default.
• W2895933654 creator A5038643879 @default.
• W2895933654 creator A5051352882 @default.
• W2895933654 creator A5057755017 @default.
• W2895933654 creator A5061973648 @default.
• W2895933654 creator A5064653083 @default.
• W2895933654 creator A5067532930 @default.
• W2895933654 creator A5071420169 @default.
• W2895933654 creator A5076913129 @default.
• W2895933654 creator A5078114527 @default.
• W2895933654 creator A5080351994 @default.
• W2895933654 date "2018-10-19" @default.
• W2895933654 modified "2023-10-18" @default.
• W2895933654 title "Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression" @default.
• W2895933654 cites W1555945582 @default.
• W2895933654 cites W1560279371 @default.
• W2895933654 cites W1654478997 @default.
• W2895933654 cites W1751873670 @default.
• W2895933654 cites W1960036794 @default.
• W2895933654 cites W1962442902 @default.
• W2895933654 cites W1975609403 @default.
• W2895933654 cites W1979070712 @default.
• W2895933654 cites W1989854777 @default.
• W2895933654 cites W1995039837 @default.
• W2895933654 cites W1999343166 @default.
• W2895933654 cites W2004412542 @default.
• W2895933654 cites W2005302422 @default.
• W2895933654 cites W2009386327 @default.
• W2895933654 cites W2014751188 @default.
• W2895933654 cites W2021466588 @default.
• W2895933654 cites W2025039322 @default.
• W2895933654 cites W2029436832 @default.
• W2895933654 cites W2033004457 @default.
• W2895933654 cites W2037511256 @default.
• W2895933654 cites W2047166906 @default.
• W2895933654 cites W2047222465 @default.
• W2895933654 cites W2049372779 @default.
• W2895933654 cites W2071753433 @default.
• W2895933654 cites W2089561494 @default.
• W2895933654 cites W2094088075 @default.
• W2895933654 cites W2098970296 @default.
• W2895933654 cites W2099655761 @default.
• W2895933654 cites W2099970679 @default.
• W2895933654 cites W2115694405 @default.
• W2895933654 cites W2119504728 @default.
• W2895933654 cites W2140804609 @default.
• W2895933654 cites W2149131962 @default.
• W2895933654 cites W2156025284 @default.
• W2895933654 cites W2169669596 @default.
• W2895933654 cites W2169725967 @default.
• W2895933654 cites W2170055174 @default.
• W2895933654 cites W2187721367 @default.
• W2895933654 cites W2191554571 @default.
• W2895933654 cites W2400794200 @default.
• W2895933654 cites W2491436916 @default.
• W2895933654 cites W2521409454 @default.
• W2895933654 cites W2525190534 @default.
• W2895933654 cites W2528305152 @default.
• W2895933654 cites W2528897263 @default.
• W2895933654 cites W2551016134 @default.
• W2895933654 cites W2570618306 @default.
• W2895933654 cites W2610540653 @default.
• W2895933654 cites W2788392735 @default.
• W2895933654 doi "https://doi.org/10.18632/oncotarget.26239" @default.
• W2895933654 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6219671" @default.
• W2895933654 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30450161" @default.
• W2895933654 hasPublicationYear "2018" @default.
• W2895933654 type Work @default.
• W2895933654 sameAs 2895933654 @default.
• W2895933654 citedByCount "10" @default.
• W2895933654 countsByYear W28959336542018 @default.
• W2895933654 countsByYear W28959336542019 @default.
• W2895933654 countsByYear W28959336542020 @default.
• W2895933654 countsByYear W28959336542021 @default.
• W2895933654 countsByYear W28959336542022 @default.
• W2895933654 crossrefType "journal-article" @default.
• W2895933654 hasAuthorship W2895933654A5000198604 @default.
• W2895933654 hasAuthorship W2895933654A5015865144 @default.
• W2895933654 hasAuthorship W2895933654A5026049304 @default.
• W2895933654 hasAuthorship W2895933654A5038465132 @default.
• W2895933654 hasAuthorship W2895933654A5038643879 @default.
• W2895933654 hasAuthorship W2895933654A5051352882 @default.
• W2895933654 hasAuthorship W2895933654A5057755017 @default.
• W2895933654 hasAuthorship W2895933654A5061973648 @default.
• W2895933654 hasAuthorship W2895933654A5064653083 @default.
• W2895933654 hasAuthorship W2895933654A5067532930 @default.
• W2895933654 hasAuthorship W2895933654A5071420169 @default.
• W2895933654 hasAuthorship W2895933654A5076913129 @default.
• W2895933654 hasAuthorship W2895933654A5078114527 @default.
• W2895933654 hasAuthorship W2895933654A5080351994 @default.
• W2895933654 hasBestOaLocation W28959336541 @default.
• W2895933654 hasConcept C104317684 @default.
• W2895933654 hasConcept C119056186 @default.

• next